Skip to main content
PAHC
NASDAQ Life Sciences

Controlling Shareholder Establishes New $24.9M Stock Sale Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$33.26
Mkt Cap
$1.349B
52W Low
$22.51
52W High
$60.08
52W Position info
48% above low
Off High info
45% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

PAHC sits 48% above its 52-week low of $22.51.

Summary

A controlling shareholder has initiated a new Rule 10b5-1 plan to sell up to $24.9 million in stock, adding to recent sales and indicating ongoing insider distribution.


Key Events · Ownership and Investor Activity · PAHC

  • New 10b5-1 Sales Plan Established

    Jack C. Bendheim's entity, BFI Co., LLC, adopted a new Rule 10b5-1 plan to sell up to 750,000 shares of Class A Common Stock through March 2027, with sales commencing in September 2026.

  • Significant Future Selling Pressure

    The shares covered by the new plan are valued at approximately $24.9 million, representing about 1.85% of the company's current market capitalization, indicating a substantial future overhang.

  • Ongoing Insider Sales

    The filing also disclosed additional sales of 39,728 shares between April 28 and May 7, 2026, totaling approximately $2.56 million, continuing a trend of distribution by the controlling shareholder.

  • Controlling Stake Maintained

    Despite the sales and future plan, Jack C. Bendheim and BFI Co., LLC will continue to beneficially own a controlling stake of approximately 48.2% of the company's common stock.


Analysis · PAHC · Life Sciences

Jack C. Bendheim, a controlling shareholder, has established a new Rule 10b5-1 plan to sell up to 750,000 shares, valued at approximately $24.9 million based on current prices. This plan, set to begin in September 2026, signals a significant future selling pressure from a major insider. The filing also reports additional sales of approximately $2.56 million since the last amendment, continuing a pattern of distribution by the insider.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PAHC was trading at $33.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $22.51 to $60.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PAHC - Latest Insights

PAHC
Nov 04, 2026, 4:22 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $39.32
Real-time Price: $33.29 info
Change: -$6.03 (-15%) info
Market Cap: $1.352B info
PAHC
Aug 26, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.93
Real-time Price: $33.29 info
Change: -$2.64 (-7%) info
Market Cap: $1.352B info
PAHC
Aug 26, 2026, 4:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $35.93
Real-time Price: $33.29 info
Change: -$2.64 (-7%) info
Market Cap: $1.352B info
PAHC
Aug 26, 2026, 4:14 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $35.93
Real-time Price: $33.29 info
Change: -$2.64 (-7%) info
Market Cap: $1.352B info
PAHC
Jun 26, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.69
Real-time Price: $33.29 info
Change: +$1.60 (+5%) info
Market Cap: $1.352B info